Biologictx® Is A Proud Pharmacy Provider For Envarsus® XR
New Medication To Combat Organ Rejection In Kidney Transplant PatientsAnticipated To Be Available December 7, 2015
New Medication To Combat Organ Rejection In Kidney Transplant PatientsAnticipated To Be Available December 7, 2015
TOTOWA, N.J., Dec. 1, 2015 /PRNewswire/ -- BiologicTx®, a transplant-focused specialty pharmacy, today announced that they have access to Veloxis Pharmaceuticals' new product Envarsus® XR (tacrolimus extended-release tablets). Veloxis Pharmaceuticals anticipates Envarsus® XR to be available to patients on December 7, 2015.
Envarsus® XR is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants. Envarsus XR is taken once daily on an empty stomach and should not be used or substituted with any other tacrolimus products. Please click here for complete information on Envarsus® XR.
"BiologicTx primary focus and responsibility is to provide the transplant patient with the best possible products to help maintain their health and longevity of their transplanted organ," said Sal Rafanelli, RPh, Chief Executive Officer and Co-Founder of BiologicTx. "The ability to offer a product like Envarsus® XR allows us continue to provide the best possible medications to our patient population."
To refer patients to BiologicTx for access to Envarsus® XR, please click here to complete the Envarsus® XR referral form and fax into BiologicTx at 877-567-8089.
About BiologicTx®
BiologicTx® is a national specialty pharmacy that joins the administration of therapeutics, research, and digital health to advance the practice of solid organ transplant and chronic specialties. BiologicTx is comprised of four operating segments: BiologicTx Pharmacy and Therapeutic Services; BiologicTx Clinical Trials™, which designs, sponsors, and aggregates clinical data, assisting in the publication of multicenter studies; BiologicTx Discovery 2 Life™, which includes digital health platforms including BiologicTx Sequence™ and BiologicTx MatchGrid™, BiologicTx Paired Donation™, which offers an advanced software matching system, MatchGrid, and clinical decision intelligence to transplant centers. For more information, visit us at: www.BiologicTx.com.
| Media Contact: |
Tara Marchese |
| 1-877-567-8087 |
|
Logo - http://photos.prnewswire.com/prnh/20130520/LA16505LOGO
SOURCE BiologicTx
Share this article